News

Salvage Ipilimumab Plus Nivolumab Active in Metastatic RCC

Ipilimumab plus nivolumab yielded anti-tumor activity with acceptable toxicity in patients with metastatic renal cell carcinoma (RCC) previously given immune checkpoint inhibitor (ICI) therapy (J Clin Oncol. 2020 Jun 3. Epub ahead of print).

“The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the [PD-1] pathway remains unknown,” according to Anita Gul, MD, Cleveland Clinic Taussig Cancer Institute, Ohio, and co-investigators.

Thus, the researchers evaluated ipilimumab therapy plus nivolumab in patients with metastatic RCC after previous anti-PD-1 treatment.

A total of 45 patients with metastatic RCC were included in the study and given a combination of ipilimumab and nivolumab.

The primary end points of the study were objective response rate and progression-free survival.  Toxicity was also assessed.

At a median follow-up of 12 months, the objective response rate was 20%. The median progression-free survival was 4 months.

Ultimately, 29 (64%) patients had immune-related adverse events. Of these patients, 6 had grade 3 immune-related adverse events.

“Ipilimumab and nivolumab demonstrated antitumor activity with acceptable toxicity in patients with metastatic RCC who had prior treatment with checkpoint inhibition,” Dr Gul et al concluded.—Kaitlyn Manasterski

Stay in the know.
OncNet Newsletter